ImmunoScape:IMMUNOSCAPE: ENTERED IN-LICENSING DEAL WITH CUE BIOPHARMA FOR DEVELOPMENT OF NEW CLASS OF THERAPIES TO ATTACK SOLID TUMOR CANCERS